Protagonist Therapeutics, Inc (PTGX)
Health Care ยท Pharmaceutical Preparations
Protagonist Therapeutics, Inc (PTGX) is listed on Nasdaq, where its shares have traded since August 11, 2016. SentiSense covers Protagonist Therapeutics, Inc in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Dinesh V. Patel is its chief executive officer. The company reports 141 employees, and its corporate website is www.protagonist-inc.com.
About Protagonist Therapeutics, Inc
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform. The company focuses on three therapeutic areas: inflammation and immunology, hematology, and metabolic diseases. Its pipeline includes clinical-stage and preclinical candidates such as rusfertide for polycythemia vera, icotrokinra for inflammatory diseases, and other programs targeting IL-17, obesity, and iron metabolism disorders, developed through internal research and strategic collaborations.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 334 institutions reported holding PTGX, with 75.8 million shares worth $9.3 billion in aggregate. The largest reported holders were BlackRock, Vanguard and Farallon Capital Management. Of the 5 largest reported holders, 3 added shares, 1 reduced its position and 1 held its position unchanged during the quarter.
More on PTGX
- PTGX sentiment: whether news and social coverage of Protagonist Therapeutics, Inc leans bullish or bearish, and the stories driving it.
- PTGX ownership: all 334 reporting institutions, plus insider and congressional trades.
- PTGX financials: revenue, net income, operating margin and free cash flow by quarter and year.
SentiSense also tracks daily options readings for Protagonist Therapeutics, Inc: IV rank, put/call percentile, 25-delta skew and open-interest walls.
Frequently asked questions
What does Protagonist Therapeutics, Inc do?
Protagonist Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of peptide-based therapeutics using its proprietary technology platform.
What sector is PTGX in?
SentiSense classifies Protagonist Therapeutics, Inc in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does PTGX stock trade?
Protagonist Therapeutics, Inc (PTGX) is listed on Nasdaq, where its shares have traded since August 11, 2016.
Who is the CEO of Protagonist Therapeutics, Inc?
Dinesh V. Patel is the chief executive officer of Protagonist Therapeutics, Inc.